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Abstract: Rhythm control therapy by sodium channel blockers is widely performed for 
the   treatment of paroxysmal atrial fibrillation. Here, we present a case of acquired Brugada 
  syndrome by pill-in-the-pocket treatment using pilsicainide. It is important that this therapy 
should be applied only after confirming the drug safety to the patients.
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Case report
A 62-year-old male was transferred to the emergency department due to   presyncopal 
attacks developed after taking pilsicainide. The patient has history of   paroxysmal 
atrial fibrillation and stroke and was treated by cibenzoline 300 mg/day in 
  combination with adequate anticoagulation. Since his atrial fibrillation could 
not be suppressed by cibenzoline alone, his home doctor prescribed additional 
  pilsicainide of 100 mg for pill-in-the-pocket treatment. This was a first attempt of 
the pill-in-the-pocket treatment for this patient. His electrocardiography (ECG) 
on arrival shows 2 to 1 atrial flutter, interventricular conduction disturbance, and 
coved-type ST segment elevation in leads V1-2 consistent with type I Brugada 
ECG1 (Figure 1). His previous ECG taken during daily cibenzoline treatment did 
not show these abnormalities (Figure 2). His serum electrolyte and renal function 
were normal. Antiarrhythmic drugs were terminated after admission and the ECG 
returned normal and his clinical course was uneventful. Based on the ECG findings 
on admission, there are 2 possible causes of the presyncopal attacks in this patient. 
One possibility is due to nonsustained ventricular fibrillation which was associated 
with Brugada syndrome, and another possibility is 1 to 1 atrio-ventricular conduction 
during the atrial flutter. Sodium channel blockers are now widely used for rhythm 
control therapy for paroxysmal atrial fibrillation.2 However, physicians must care 
for the side effects. The class Ic drug can unmask Brugada syndrome or induce 
atrial flutter called “Ic flutter”. The pill-in-the-pocket treatment for atrial fibrilla-
tion is recognized as safe and effective therapy for the rhythm control for the atrial 
  fibrillation.3 It is important that this therapy should be applied after confirming the 
drug safety to the patients.Drug, Healthcare and Patient Safety
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Figure 1 electrocardiography on admission.
Figure 2 Previous electrocardiography taken during daily cibenzoline alone.
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